PTGX

Protagonist Therapeutics, Inc
Data: 2026-01-30
$81.8
Price
3.22%
Change
$96.54
52W High
$33.7
52W Low

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Quick Stats
Jan 30, 2026

48.4

AI Score

HOLD

1.63

Volume Ratio

Feb 20, 2026

Next Earnings

15

+ve Days (30d)

15

-ve Days (30d)

PTGX Stock Summary

Last updated Jan 30, 2026

PTGX is currently trading at $81.8, positioned above its 200-day moving average of $65.33, indicating a long-term uptrend. The stock has a 52-week range of $33.7 to $96.54.

Technical Analysis: The 50-day moving average stands at $86.15, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 44.876, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.125, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates PTGX at 48.4/100 with a HOLD recommendation.

PTGX (Protagonist Therapeutics, Inc) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 44.876
CMF (20) 0.125
ROC (10) -3.481
ADX (14) 20.262
Indicator Value
MACD (12,26,9) -1.083
AROONOSC (14) -64.286
WILLAMS %R (14) -57.876
MFI (14) 59.951
PTGX Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

PTGX Price vs Max Options Open Interest
PTGX Max Change In Options Open Interest

PTGX Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PTGX Daily Out of Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PTGX Daily In the Money Options - Sort by Max open Interest (near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PTGX Most Active Options by Volume(near term)

1st February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Protagonist Therapeutics, Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

PTGX Moving Averages Analysis

Protagonist Therapeutics, Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026

PTGX (Protagonist Therapeutics, Inc) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 82.64
20 82.72
30 84.39
50 86.15
100 78.89
200 65.33

PTGX Fundamental Analysis

P/E (Forward) 26.3852
P/E (Trailing) 119.6197
Market Cap ($) 4.9 billion
Earnings/Share ($) 0.66
Net Proft Margin (%) 0.2194
Dividend/Share ($) --
EPS Estimate Current Year ($) -1.8708
EPS Estimate Next Year ($) 1.0616
WallStreet Target Price ($) 96.3333
Most Recent Quarter